|
Sarcoma
|
C04.557.450.795 |
|
|
Colorectal Neoplasms
|
D015179 |
[Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
] |
|
Ribosome Inactivating Proteins
|
D054788 |
[N-Glycosidases that remove adenines from RIBOSOMAL RNA, depurinating the conserved alpha-sarcin loop of 28S RIBOSOMAL RNA. They often consist of a toxic A subunit and a binding lectin B subunit. They may be considered as PROTEIN SYNTHESIS INHIBITORS. They are found in many PLANTS and have cytotoxic and antiviral activity.
] |
|
Ribosome Inactivating Proteins, Type 1
|
D054789 |
[Ribosome inactivating proteins consisting of only the toxic A subunit, which is a polypeptide of around 30 kDa.
] |
|
Infratentorial Neoplasms
|
D015192 |
[Intracranial tumors originating in the region of the brain inferior to the tentorium cerebelli, which contains the cerebellum, fourth ventricle, cerebellopontine angle, brain stem, and related structures. Primary tumors of this region are more frequent in children, and may present with ATAXIA; CRANIAL NERVE DISEASES; vomiting; HEADACHE; HYDROCEPHALUS; or other signs of neurologic dysfunction. Relatively frequent histologic subtypes include TERATOMA; MEDULLOBLASTOMA; GLIOBLASTOMA; ASTROCYTOMA; EPENDYMOMA; CRANIOPHARYNGIOMA; and choroid plexus papilloma (PAPILLOMA, CHOROID PLEXUS).
] |
|
Chorionic Villi Sampling
|
D015193 |
[A method for diagnosis of fetal diseases by sampling the cells of the placental chorionic villi for DNA analysis, presence of bacteria, concentration of metabolites, etc. The advantage over amniocentesis is that the procedure can be carried out in the first trimester.
] |
|
Blood Glucose Self-Monitoring
|
D015190 |
[Self evaluation of whole blood glucose levels outside the clinical laboratory. A digital or battery-operated reflectance meter may be used. It has wide application in controlling unstable insulin-dependent diabetes.
] |
|
Dimethyl Adipimidate
|
D02.241.081.337.052.250 |
|
|
Adipates
|
D02.241.081.337.052 |
|
|
Muscular Dystrophy, Oculopharyngeal
|
D039141 |
[An autosomal dominant hereditary disease that presents in late in life and is characterized by DYSPHAGIA and progressive ptosis of the eyelids. Mutations in the gene for POLY(A)-BINDING PROTEIN II have been associated with oculopharyngeal muscular dystrophy.
] |
|
Myelography
|
E01.370.350.700.560.505 |
|
|
Neuroradiography
|
E01.370.350.700.560 |
|
|
Carcinogenicity Tests
|
D015197 |
[Tests to experimentally measure the tumor-producing/cancer cell-producing potency of an agent by administering the agent (e.g., benzanthracenes) and observing the quantity of tumors or the cell transformation developed over a given period of time. The carcinogenicity value is usually measured as milligrams of agent administered per tumor developed. Though this test differs from the DNA-repair and bacterial microsome MUTAGENICITY TESTS, researchers often attempt to correlate the finding of carcinogenicity values and mutagenicity values.
] |
|
Chlorophyll A
|
D03.633.400.909.374.140 |
|
|
Chlorophyll
|
D03.633.400.909.374 |
|
|
Diffusion Chambers, Culture
|
D015194 |
[Devices used in a technique by which cells or tissues are grown in vitro or, by implantation, in vivo within chambers permeable to diffusion of solutes across the chamber walls. The chambers are used for studies of drug effects, osmotic responses, cytogenic and immunologic phenomena, metabolism, etc., and include tissue cages.
] |
|
Drug Design
|
D015195 |
[The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include pharmacokinetics, dosage analysis, or drug administration analysis.
] |
|
Consummatory Behavior
|
F01.145.113.252 |
|
|
Behavior, Animal
|
F01.145.113 |
|
|
Holocarboxylase Synthetase Deficiency
|
C16.320.565.100.620.380 |
|
